SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazilian election developments and relief over Nu Holdings statement that it is not pursuing a Monzo deal are driving discussion of the rebound. Traders are hopeful the recovery continues, while others doubt the move will hold and frame it as a short squeeze.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Toshibas plan to expand hard-disk capacity for AI data centers has sparked concern that added supply could challenge Western Digitals market share and pricing power, driving a sharp selloff in WDC and Seagate. Traders are divided: many call the reaction excessive because the expansion will take time and HDD demand remains strong, while others see a credible medium-term competitive risk.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Sam Altmans statement that OpenAI remains closely engaged with Cerebras has reassured traders after a report raised concerns that OpenAIs latest Ultrafast mode would rely on Nvidia GPUs instead. Bulls see the comments as reaffirming the partnership, while others remain cautious about insider share unlocks and selling pressure.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Attention centers on Blooms role in supplying onsite power for AI data centers, particularly Oracles Project Jupiter: traders cite reassurances that the fuel-cell commitment remains intact, along with S&P 500 inclusion and manufacturing expansion, as support for the shares. Optimism about power demand and backlog growth is tempered by concerns over project execution, valuation, and sharp trading swings.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus ARCT-810 Phase 2 update for OTC deficiency and unveiling of its LUNAR 2.0 delivery platform are driving discussion, alongside plans to add ARCT-2601 and acquire myNEO. Many traders view the clinical findings and platform progress positively, while others question the delayed timelines and added spending and say the update fell short of expectations.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss reported 48% estimated three-year survival with investigational BOT+BAL in recurrent ovarian cancer is driving discussion, with bullish traders pointing to durable survival and possible regulatory relevance. Others caution that the results come from a small, nonrandomized Phase 1b cohort and do not establish FDA approval or confirmatory benefit.

Stablecoin Development Corp. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in West Palm Beach, FL.

Stablecoin Development Corp.

SDEVs sharp, high-volume rally is drawing momentum-trading attention, with traders speculating about a low-float short squeeze and linking the move to gains in SKY, the token held in the companys treasury. Others say the surge lacks a confirmed company catalyst and warn about potential dilution and a sharp reversal.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys QNX momentum is driving attention, especially a record Alloy Kore design win for the Coretura vehicle platform, a newly disclosed Uber design win, and stronger results with raised guidance. Many traders see these developments as evidence of growth in software-defined vehicles and physical AI, while others question how quickly the wins will translate into revenue and have debated the stocks volatile, sometimes muted reaction.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Discussion centers on DefenCaths outlook after the transition from temporary TDAPA payments, with traders debating whether future CMS or Medicare Advantage reimbursement and wider adoption can offset pricing pressure. Views are split: some see DaVitas rollout and real-world evidence as support for growth, while others worry that ClearGuard comparisons and uncertainty about reimbursement limit the products commercial potential.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramounts court-cleared Warner Bros. Discovery acquisition and planned integration are driving attention, with traders focused on the warrant distribution and transition to the Skydance name and NYSE listing. Bulls see the combined studios and streaming assets as a stronger competitor, while bears cite heavy acquisition debt, dilution and financing costs as risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Equity

Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year.


OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.

Ocugen (OCGN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?

Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.

OCGN's Catalyst Calendar for Trial Data and Filings Through 2028

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.

This account has been verified as an official OCGN representative.

Verified Account

Ocugen

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Ocugen Inc

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be this week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.06	--	--	N/A
Q2 '26	-$0.05	-$0.07	-31.25%	MISSED
Q1 '26	-$0.05	-$0.06	-16.67%	MISSED
Q4 '25	-$0.06	-$0.06	-2.65%	MISSED
Q3 '25	-$0.06	-$0.07	-25.00%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

OCGN Earnings

Upcoming Earnings: Q3 '26

Historical Earnings